Mather Group LLC. Takes Position in DexCom, Inc. (NASDAQ:DXCM)

Mather Group LLC. purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 885 shares of the medical device company’s stock, valued at approximately $123,000.

Several other hedge funds have also recently bought and sold shares of the business. Stableford Capital II LLC grew its holdings in shares of DexCom by 2.1% during the 4th quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after acquiring an additional 88 shares in the last quarter. D Orazio & Associates Inc. raised its stake in shares of DexCom by 0.8% during the 4th quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock worth $1,534,000 after purchasing an additional 93 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of DexCom by 10.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock valued at $133,000 after buying an additional 98 shares during the last quarter. Valley National Advisers Inc. grew its stake in shares of DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares in the last quarter. Finally, FORVIS Wealth Advisors LLC increased its holdings in DexCom by 0.7% in the fourth quarter. FORVIS Wealth Advisors LLC now owns 16,381 shares of the medical device company’s stock worth $2,033,000 after buying an additional 110 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $116.64 on Friday. The firm has a market capitalization of $46.39 billion, a price-to-earnings ratio of 75.25, a PEG ratio of 2.85 and a beta of 1.22. DexCom, Inc. has a one year low of $74.75 and a one year high of $142.00. The business has a fifty day simple moving average of $125.29 and a 200 day simple moving average of $125.84. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The company had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. Sell-side analysts expect that DexCom, Inc. will post 1.78 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 4,137 shares of the stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $140.00, for a total value of $579,180.00. Following the completion of the transaction, the executive vice president now directly owns 76,304 shares of the company’s stock, valued at approximately $10,682,560. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other DexCom news, EVP Michael Jon Brown sold 2,624 shares of the company’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $140.04, for a total transaction of $367,464.96. Following the sale, the executive vice president now directly owns 68,682 shares of the company’s stock, valued at $9,618,227.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Sadie Stern sold 4,137 shares of DexCom stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $140.00, for a total transaction of $579,180.00. Following the completion of the transaction, the executive vice president now owns 76,304 shares of the company’s stock, valued at approximately $10,682,560. The disclosure for this sale can be found here. Insiders sold a total of 61,837 shares of company stock worth $8,490,675 over the last quarter. Company insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on DXCM shares. UBS Group boosted their target price on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Raymond James boosted their price target on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 26th. Canaccord Genuity Group increased their price objective on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday, April 26th. Citigroup boosted their target price on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Finally, Redburn Atlantic started coverage on DexCom in a report on Thursday, May 30th. They set a “neutral” rating and a $130.00 price target on the stock. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $140.94.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.